Drug Discovery World, Drug Discovery and Development News

Automated compound management evolves to meet the drug discovery demands of the future

By Dr Caroline Engeloch and Dr Daniel Baeschlin

The development of new drugs involves testing hundreds of thousands of compounds, from high throughput screening through to subsequent lead optimization.

Disruptive change by linked data and semantic technologies in healthcare and life sciences

By Hans Constandt

From early days the sharing of knowledge has been one of the main forces driving science and innovation. Yet latterly, the pharmaceutical industry with its fear of loss of intellectual property has stalled the engine that has given so many beneficial outcomes.

Outsourced Kinase Profiling Services, adding value to in-house kinase programmes

Dr John Comley

Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry, demonstrated by the large number of service providers offering outsourced kinase profiling services.

Fluorescence Lifetime Assays

By Dr Graham Cotton, Dr Wayne Bowen, Dr Robert Grundy and Dr Ulrich Hassiepen

The benefits of fluorescence lifetime (FLT)-based technologies have been highlighted for more than a decade but thus far they have failed to gain widespread acceptance.

Gene Editing: Re-writing genomes with targetable nucleases

By Dr Dana Carroll

We are in the midst of a revolution in genome engineering, based on reagents that can be designed to cut chromosomal DNA at arbitrary sites. These targetable nucleases allow creation of new mutations at specific sites, introduction of designed sequence changes and production of larger alterations, as desired by the experimenter. They are being used to explore gene function and create disease models and they hold great promise for human gene therapy.

Evolving strategies for application-specific validation of research use antibodies

By Dr A Solache, R Brockett, T Chuang, Dr R Clark, R Dimagiba, Dr A Fisher, Dr W Speckmann & Dr C Yang

Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting , immunoprecipitation, flow cytometry, enzyme-linked immunosorbent assays, quantitative immunofluorescence) and immunohistochemistry .

The great neuro-pipeline "brain drain" (and why Big Pharma hasnât given up on CNS disorders)

By Julia Skripka-Serry

Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Yet they have become as much a vice as a potential virtue.

Partnering with the right CRO is a winning strategy for companies big and small

By Dr Davide Molho

The Bio-Pharma business model is undergoing radical changes. Over the last two decades, we have seen a number of changes as the biopharmaceutical industry has gradually become more willing to look externally and embrace the concept of outsourcing as it looks for new sources of discovery and innovation.

Biomarker discovery: the need for new generation peptideprotein microarrays

By Dr N Schwabe and K Catchpole

The progression from health to disease is marked by significant biological changes within an individual. Clinically presenting symptoms, however, can be non-specific and variable enough to hinder diagnosis, and may appear only after a disease has already become well-established and consequently more difficult to treat.

	Drug Discovery	Business	Chemistry	Enabling Technologies
	Informatics	Personalised Medicine	Screening	Therapeutics

Automated compound management evolves to meet the drug discovery demands of the future

Disruptive change by linked data and semantic technologies in healthcare and life sciences

Outsourced Kinase Profiling Services, adding value to in-house kinase programmes

Fluorescence Lifetime Assays

Gene Editing: Re-writing genomes with targetable nucleases

Evolving strategies for application-specific validation of research use antibodies

The great neuro-pipeline "brain drain" (and why Big Pharma hasnât given up on CNS disorders)

Partnering with the right CRO is a winning strategy for companies big and small

Biomarker discovery: the need for new generation peptideprotein microarrays

NTRC provides high-throughput screening services together with Pivot Park Screening Centre

Fluxion launches High Throughput Quattro Array for BioFlux

Argenta announces fourth extension of drug discovery collaboration with Genentech

NEW Microplate Hotel for TAPâs CompacT SelecT Extends Screening System Support

LINGUAMATICS ENHANCES ACCESS TO CONTENT WITH LATEST RELEASE OF TEXT MINING PLATFORM

Reinnervate Ltd and Roslin Cellab to partner around 3D stem cell printing products and technologies

	GE Healthcare If life were a game and scientists superheroes, this is what drug discovery might look like....

	Thermo Scientific Make your automated workflow a reality with iAutomate. See how this new online tool can help.